Faheem Hasnain

Co-Founder at Gossamer Bio, Inc.

Faheem Hasnain

Faheem Hasnain

Co-Founder at Gossamer Bio, Inc.

Overview
Career Highlights

Oncology Therapeutics Network Corp.
Receptos LLC
Abbott Biotherapeutics Corp.

RelSci Relationships

2112

Number of Boards

19

Birthday

1959

Age

62

Contact Data
Trying to get in touch with Faheem Hasnain? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Faheem Hasnain likely has professional access to. A relationship does not necessarily indicate a personal connection.

Executive Chairman at Ventyx Biosciences, Inc.

Relationship likelihood: Strong

Venture Partner at ARCH Venture Partners

Relationship likelihood: Strong

Founder at SENTÉ, Inc. (California)

Relationship likelihood: Strong

Co-Founder, Director at Refuge Biotechnologies, Inc.

Relationship likelihood: Strong

Executive Chairman at PureTech Health PLC

Relationship likelihood: Strong

Managing Partner & Founder at The Column Group LLC

Relationship likelihood: Strong

Chairman & Co-Founder at Avidity Biosciences LLC

Relationship likelihood: Strong

Executive Chair at Atara Biotherapeutics, Inc.

Relationship likelihood: Strong

Secretary, General Counsel & Executive Vice President at Gossamer Bio, Inc.

Relationship likelihood: Strong

Co-Founder at Clovis Oncology, Inc.

Relationship likelihood: Strong

Paths to Faheem Hasnain
Potential Connections via
Relationship Science
You
Faheem Hasnain
Co-Founder at Gossamer Bio, Inc.
Education
B.Ed

The University of Windsor is a comprehensive, student-centred university, with more than 16,500 students enrolled in a broad range of undergraduate and graduate programs including several professional schools such as Law, Business, Engineering, Education, Nursing, Human Kinetics and Social Work. The year 2013 will mark the University of Windsor's 50th anniversary as a public institution, but the story of our university actually began with its founding in September of 1857, when the first students arrived to study at its predecessor, Assumption College.

Career History
President, Oncology Therapeutics Network
2002 - 2004

Bristol-Myers Squibb Company Our company has a strong legacy of innovation that began in New York in 1858 when Edward R. Squibb, M.D., founded a pharmaceutical company in Brooklyn, and in 1887 when two friends, William McLaren Bristol and John Ripley Myers purchased a struggling drug manufacturing firm in Clinton. Together, they laid the foundation for our company today — a global BioPharma leader that continues this legacy of innovation.

Vice President-Global eBusiness
1988 - 2002

GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

President & Chief Executive Officer
2008 - 2010

Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA.

Boards & Committees
Chairman, Board of Directors
2020 - Current

Aspen Neuroscience, Inc. engages in the provision of neurological treatment services. It offers technologies for patient-specific induced pluripotent stem cell-based therapies. The company was founded by Jeanne Loring and is headquartered in San Diego, CA.

Chairman, Board of Directors
2019 - Current

Mirati Therapeutics, Inc. operates as a clinical-stage oncology company, which engages in the development of novel therapeutics. The firm's products targets the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995 and is headquartered in San Diego, CA.

Independent Director
2015 - Current

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia; KO-947 which is an ERK inhibitor for MAPK Pathway Tumors; and KO-539 which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in La Jolla, CA.

Member, Board of Overseers
Current

The Scripps Research Institute (TSRI), one of the world's largest, private, non-profit research organizations, stands at the forefront of basic biomedical science, a vital segment of medical research that seeks to comprehend the most fundamental processes of life. Over the last decades, the institute has established a lengthy track record of major contributions to the betterment of health and the human condition. The institute — which is located on campuses in La Jolla, California, and Jupiter, Florida — has become internationally recognized for its research into immunology, molecular and cellular biology, chemistry, neurosciences, autoimmune diseases, cardiovascular diseases, virology, and synthetic vaccine development. Particularly significant is the institute's study of the basic structure and design of biological molecules; in this arena TSRI is among a handful of the world's leading centers. The institute’s educational programs are also top-rate. The Kellogg School of Science and Technology is currently ranked among the best in the nation in its fields of biology and chemistry. Rather than isolating faculty members, students, and laboratories into separate and distinct disciplines, as is generally prescribed in universities, a cooperative, collaborative spirit is encouraged and embraced. While the level of scientific investigation is intense, the atmosphere is collegial, relaxed, and informal. Technicians, postdoctoral fellows, graduate students, and administrative support staff all are considered part of the team and are given the latitude and responsibility to accomplish their tasks so as to serve the best interests of science. The pursuit of scientific excellence is paramount and all efforts are directed toward that end. The bulk of the institute's funding is derived from the National Institutes of Health and other federal agencies. In today's environment of increasing competition for shrinking federal dollars, however, collaborative industrial partnerships with leading pharmaceutical companies provide additional funding in several areas key to the organization's research objectives. The Scripps Research Institute's adherence to the highest scientific standards, emphasis on a multidisciplinary approach to problem solving, participation in the perpetuation of knowledge through education, and continual pursuit of research excellence provide an unparalleled scientific environment.

Board Member (Partial Year)
Prior - 2015

Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers.

Non-Profit Donations & Grants

Learn how non-profit organizations benefit from RelSci
$250K - $500K
2019

William J. Clinton Foundation works to alleviate poverty, improve global health, strengthen economies, and protects the environment, by fostering partnerships among governments, businesses, nongovernmental organizations (NGOs) and private citizens. The foundation focuses on worldwide issues that demand urgent action, solutions, and measurable results - global climate change, HIV/AIDS in the developing world, childhood obesity & economic opportunity in the United States, and economic development in Africa and Latin America.

Transactions
Details Hidden

Receptos LLC issued USD Common Stock

Details Hidden

Receptos LLC issued USD Common Stock

Details Hidden

Receptos LLC issued USD Common Stock

Investments
Details Hidden

Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi on October 25, 2015 and is headquartered in San Diego, CA.

Details Hidden

Receptos LLC engages in the provision of developing and commercializing of therapeutic candidates for the treatment of immune and inflammatory diseases. It offers Ozanimod for relapsing multiple sclerosis, Ozanimod for inflammatory bowel disease and RPC4046 for eosinophilic esophagitis. The company was founded by Marcus F. Boehm, Robert J. Peach, William H. Rastetter, Hugh Rosen and Raymond C. Stevens on September 26, 2008 and is headquartered in San Diego, CA.

Details Hidden

Vital Therapies, Inc. operates as a biotherapeutic company, which develops a cell-based therapy targeting the treatment of acute forms of liver failure. Its product candidate, ELAD System, is a human cell-based bio-artificial liver support system that operates outside the body or extracorporeal. The company was founded in May 2003 and is headquartered in San Diego, CA.

Public Holdings
Restricted data only for RelSci Enterprise users.
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Faheem Hasnain. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Faheem Hasnain's profile does not indicate a business or promotional relationship of any kind between RelSci and Faheem Hasnain.